デフォルト表紙
市場調査レポート
商品コード
1490331

分散型臨床試験市場:2024-2034年

Decentralised Clinical Trials Market Report 2024-2034

出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 321 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=206.60円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

分散型臨床試験市場:2024-2034年
出版日: 2024年05月31日
発行: Visiongain Reports Ltd.
ページ情報: 英文 321 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の分散型臨床試験の市場規模は、2034年にかけてCAGR 7.6%で成長すると予測されています。

臨床試験のグローバル化:

臨床試験のグローバル化は臨床試験市場を根本から変革しています。成長の原動力となっているのは、臨床試験の増加であり、これは医療を取り巻く環境が大きく変化していることを示しています。医薬品開発のスケジュールを早め、コストを削減し、多様な患者集団に革新的な医薬品を提供する必要性が高まっています。製薬会社やバイオテクノロジー企業は、さまざまな国で包括的な臨床データを収集するため、臨床試験の実施に多額の投資を行っています。多様な集団から臨床データを収集することは、治療法の開発と有効性に大きな影響を与えます。さまざまな民族的、遺伝的、社会経済的背景を持つ参加者を含めることで、臨床試験はより包括的で一般化可能なデータを得ることができます。この多様性は、異なる集団が治療にどのように反応するかを理解するのに役立ち、均質な研究集団では明らかにならないような、薬剤の有効性や潜在的な副作用のばらつきを明らかにすることができます。

グローバル化は、さまざまな地域における規制の調和を促進する上で不可欠であり、臨床試験市場に大きなメリットをもたらします。規制当局のガイドラインや手続きを世界レベルで標準化することで、製薬企業は複雑な承認プロセスを複数の国で一度に管理しやすくなります。この連携により、冗長な作業が最小限に抑えられ、新しい治療法の開発と承認が簡素化されます。その結果、最先端の治療法の市場投入までの時間が短縮され、世界中の患者が新しい医療技術により早くアクセスできるようになります。さらに、一貫した規制の枠組みは、世界中の研究者間の協力とデータ交換を促進し、臨床試験の全体的な質と有効性を向上させます。

当レポートでは、世界の分散型臨床試験の市場を調査し、市場概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 レポート概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な調査結果
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
  • COVID-19の影響分析
  • ポーターのファイブフォース分析
  • PEST分析

第4章 分散型臨床試験市場の分析:研究設計別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 介入的
  • 観察的
  • 拡張アクセス
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第5章 分散型臨床試験市場の分析:適応症別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 腫瘍
  • 心臓血管
  • 免疫
  • 呼吸器
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第6章 分散型臨床試験市場の分析:エンドユーザー別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 製薬・バイオ医薬品企業
  • CRO
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第7章 分散型臨床試験市場の分析:コンポーネント別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • モバイル医療
  • 遠隔医療
  • ウェアラブルデバイス
  • ウェブベース技術
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第8章 分散型臨床試験市場の分析:地域別

  • 主要調査結果
  • 市場規模の推移・予測

第9章 北米の分散型臨床試験市場の分析

第10章 欧州の分散型臨床試験市場の分析

第11章 アジア太平洋の分散型臨床試験市場の分析

第12章 ラテンアメリカの分散型臨床試験市場の分析

第13章 中東・アフリカの分散型臨床試験市場の分析

第14章 企業プロファイル

  • 競合情勢
  • 戦略的展望
  • Castor
  • Clario
  • Clinical Ink
  • CLOUDZBYZ, Inc.
  • Dassault Systemes SE(Medidata Solutions, Inc.)
  • Ergomed Group
  • Florence Healthcare, Inc.
  • ICON Plc
  • IQVIA Inc.
  • KORE Wireless Group, Inc.
  • Laboratory Corporation of America Holdings(Covance)
  • Medable Inc.
  • Medrio
  • Oracle Life Sciences
  • Parexel International(MA)Corporation
  • ProPharma Group MIS Limited
  • Science 37
  • Signant Health(CRF Bracket)
  • Syneos Health
  • Thermo Fisher Scientific Inc.(PPD)
  • Veeva Systems

第15章 総論・提言

  • Visiongainによる総論
  • 市場参入企業への提言
図表

List of Tables

  • Table 1 Decentralised Clinical Trials Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
  • Table 2 Decentralised Clinical Trials Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Decentralised Clinical Trials Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Decentralised Clinical Trials Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Decentralised Clinical Trials Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 Decentralised Clinical Trials Market Study Design, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 7 Interventional Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 8 Observational Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 9 Expanded Access Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 10 Decentralised Clinical Trials Market by Indication, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 11 Oncology Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 12 Cardiovascular Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 13 Immunology Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 14 Respiratory Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 15 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 16 Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 17 Pharmaceutical & Biopharmaceutical Companies Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 18 Clinical Research Organisations (CROs) Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 19 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 20 Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 21 Mobile Healthcare Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 22 Telemedicine Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 23 Wearable Devices Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 24 Web-based Technology Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 25 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 26 Decentralised Clinical Trials Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 27 North America Decentralised Clinical Trials Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 28 North America Decentralised Clinical Trials Market Study Design, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 29 North America Decentralised Clinical Trials Market by Indication, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 30 North America Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 31 North America Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 32 U.S. Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 33 Canada Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 34 Europe Decentralised Clinical Trials Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 35 Europe Decentralised Clinical Trials Market Study Design, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 36 Europe Decentralised Clinical Trials Market by Indication, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 37 Europe Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 38 Europe Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 39 Germany Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 40 France Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 41 UK Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 42 Italy Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 43 Spain Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 44 Russia Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 45 Poland Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 46 Belgium Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 47 Rest of Europe Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 48 Asia Pacific Decentralised Clinical Trials Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 49 Asia Pacific Decentralised Clinical Trials Market Study Design, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 50 Asia Pacific Decentralised Clinical Trials Market by Indication, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 51 Asia Pacific Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 52 Asia Pacific Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 53 Japan Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 54 China Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 55 India Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 56 Australia Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 57 South Korea Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 58 Singapore Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 59 Taiwan Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 60 Rest of Asia Pacific Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 61 Latin America Decentralised Clinical Trials Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 62 Latin America Decentralised Clinical Trials Market Study Design, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 63 Latin America Decentralised Clinical Trials Market by Indication, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 64 Latin America Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 65 Latin America Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 66 Brazil Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 67 Mexico Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 68 Argentina Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 69 Colombia Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 70 Rest of Latin America Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 71 MEA Decentralised Clinical Trials Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 72 MEA Decentralised Clinical Trials Market Study Design, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 73 MEA Decentralised Clinical Trials Market by Indication, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 74 MEA Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 75 MEA Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 76 GCC Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 77 South Africa Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 78 Rest of MEA Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 79 Strategic Outlook
  • Table 80 Castor: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 81 Castor.: Product Benchmarking
  • Table 82 Castor: Strategic Outlook
  • Table 83 Clario: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 84 Clario.: Product Benchmarking
  • Table 85 Clario: Strategic Outlook
  • Table 86 Clinical Ink: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 87 Clinical Ink.: Product Benchmarking
  • Table 88 Clinical Ink: Strategic Outlook
  • Table 89 CLOUDZBYZ, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 CLOUDZBYZ, Inc..: Product Benchmarking
  • Table 91 CLOUDZBYZ, Inc.: Strategic Outlook
  • Table 92 Dassault Systemes SE (Medidata Solutions, Inc.): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 Dassault Systemes SE (Medidata Solutions, Inc.): Product Benchmarking
  • Table 94 Dassault Systemes SE (Medidata Solutions, Inc.): Strategic Outlook
  • Table 95 Ergomed Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 Ergomed Group.: Product Benchmarking
  • Table 97 Ergomed Group: Strategic Outlook
  • Table 98 Florence Healthcare, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 Florence Healthcare, Inc.: Product Benchmarking
  • Table 100 Florence Healthcare, Inc.: Strategic Outlook
  • Table 101 ICON Plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 ICON Plc: Product Benchmarking
  • Table 103 ICON Plc: Strategic Outlook
  • Table 104 IQVIA Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 IQVIA Inc.: Product Benchmarking
  • Table 106 IQVIA Inc.: Strategic Outlook
  • Table 107 KORE Wireless Group, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 KORE Wireless Group, Inc.: Product Benchmarking
  • Table 109 KORE Wireless Group, Inc.: Strategic Outlook
  • Table 110 Laboratory Corporation of America Holdings (Covance): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 Laboratory Corporation of America Holdings ( Covance): Product Benchmarking
  • Table 112 Laboratory Corporation of America Holdings ( Covance): Strategic Outlook
  • Table 113 Medable Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 114 Medable Inc..: Product Benchmarking
  • Table 115 Medable Inc.: Strategic Outlook
  • Table 116 Medrio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 117 Medrio: Product Benchmarking
  • Table 118 Oracle Life Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 119 Oracle Life Sciences: Product Benchmarking
  • Table 120 Oracle Life Sciences: Strategic Outlook
  • Table 121 Parexel International (MA) Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Parexel International (MA) Corporation: Product Benchmarking
  • Table 123 Parexel International (MA) Corporation: Strategic Outlook
  • Table 124 ProPharma Group MIS Limited.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 125 ProPharma Group MIS Limited.: Product Benchmarking
  • Table 126 ProPharma Group MIS Limited.: Strategic Outlook
  • Table 127 Science 37.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 128 Science 37.: Product Benchmarking
  • Table 129 Science 37: Strategic Outlook
  • Table 130 Signant Health (CRF Bracket): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 131 Signant Health (CRF Bracket): Product Benchmarking
  • Table 132 Signant Health (CRF Bracket): Strategic Outlook
  • Table 133 Syneos Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 134 Syneos Health: Product Benchmarking
  • Table 135 Syneos Health: Strategic Outlook
  • Table 136 Thermo Fisher Scientific Inc. (PPD): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 137 Thermo Fisher Scientific Inc. (PPD): Product Benchmarking
  • Table 138 Thermo Fisher Scientific Inc. (PPD): Strategic Outlook
  • Table 139 Veeva Systems: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 140 Veeva Systems: Product Benchmarking
  • Table 141 Veeva Systems : Strategic Outlook

List of Figures

  • Figure 1 Decentralised Clinical Trials Market Segmentation
  • Figure 2 Decentralised Clinical Trials Market by Study-Design: Market Attractiveness Index
  • Figure 3 Decentralised Clinical Trials Market by Indication: Market Attractiveness Index
  • Figure 4 Decentralised Clinical Trials Market by End-users: Market Attractiveness Index
  • Figure 5 Decentralised Clinical Trials Market by Component: Market Attractiveness Index
  • Figure 6 Decentralised Clinical Trials Market Attractiveness Index by Region
  • Figure 7 Decentralised Clinical Trials Market: Market Dynamics
  • Figure 8 Decentralised Clinical Trials Market by Region, 2024-2034 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 9 Decentralised Clinical Trials Market by Region, 2024-2034 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 10 Decentralised Clinical Trials Market by Region, 2024-2034 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 11 Decentralised Clinical Trials Market by Region, 2024-2034 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 12 Decentralised Clinical Trials Market: Porter's Five Forces Analysis
  • Figure 13 Decentralised Clinical Trials Market: PEST Analysis
  • Figure 14 Decentralised Clinical Trials Market by Study Design: Market Attractiveness Index
  • Figure 15 Decentralised Clinical Trials Market Forecast by Study Design, 2024-2034 (US$ Million, AGR %)
  • Figure 16 Decentralised Clinical Trials Market Share Forecast by Study Design 2024, 2029, 2034 (%)
  • Figure 17 Interventional Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 18 Interventional Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 19 Observational Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 20 Observational Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 21 Expanded Access Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 22 Expanded Access Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 23 Decentralised Clinical Trials Market by Indication: Market Attractiveness Index
  • Figure 24 Decentralised Clinical Trials Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 25 Decentralised Clinical Trials Market Share Forecast by Indication; 2024, 2029, 2034 (%)
  • Figure 26 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 27 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 28 Cardiovascular Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 29 Cardiovascular Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 30 Immunology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 31 Immunology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 32 Respiratory Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 33 Respiratory Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 34 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 35 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 36 Decentralised Clinical Trials Market by End-users: Market Attractiveness Index
  • Figure 37 Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 38 Decentralised Clinical Trials Market Share Forecast by End-users, 2024, 2029, 2034 (%)
  • Figure 39 Pharmaceutical & Biopharmaceutical Companies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 40 Pharmaceutical & Biopharmaceutical Companies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Clinical Research Organisations (CROs) Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 42 Clinical Research Organisations (CROs) Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 43 Others Stimulator Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 44 Others Stimulator Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 45 Decentralised Clinical Trials Market by Component: Market Attractiveness Index
  • Figure 46 Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %)
  • Figure 47 Decentralised Clinical Trials Market Share Forecast by Component, 2024, 2029, 2034 (%)
  • Figure 48 Mobile Healthcare Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 49 Mobile Healthcare Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Telemedicine Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 51 Telemedicine Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 52 Wearable Devices Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 53 Wearable Devices Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 54 Web-based Technology Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 55 Web-based Technology Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 56 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 57 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 58 Decentralised Clinical Trials Market Forecast by Region 2024 and 2034 (Revenue, CAGR %)
  • Figure 59 Decentralised Clinical Trials Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 60 Decentralised Clinical Trials Market by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 61 North America Decentralised Clinical Trials Market Attractiveness Index
  • Figure 62 North America Decentralised Clinical Trials Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 63 North America Decentralised Clinical Trials Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 64 North America Decentralised Clinical Trials Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 65 North America Decentralised Clinical Trials Market Forecast by Study Design, 2024-2034 (US$ Million, AGR %)
  • Figure 66 North America Decentralised Clinical Trials Market Share Forecast by Study Design, 2024 & 2034 (%)
  • Figure 67 North America Decentralised Clinical Trials Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 68 North America Decentralised Clinical Trials Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 69 North America Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 70 North America Decentralised Clinical Trials Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 71 North America Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %)
  • Figure 72 North America Decentralised Clinical Trials Market Share Forecast by Component, 2024 & 2034 (%)
  • Figure 73 U.S. Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 74 Canada Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 75 Europe Decentralised Clinical Trials Market Attractiveness Index
  • Figure 76 Europe Decentralised Clinical Trials Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 77 Europe Decentralised Clinical Trials Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 78 Europe Decentralised Clinical Trials Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 79 Europe Decentralised Clinical Trials Market Forecast by Study Design, 2024-2034 (US$ Million, AGR %)
  • Figure 80 Europe Decentralised Clinical Trials Market Share Forecast by Study Design, 2024 & 2034 (%)
  • Figure 81 Europe Decentralised Clinical Trials Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 82 Europe Decentralised Clinical Trials Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 83 Europe Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 84 Europe Decentralised Clinical Trials Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 85 Europe Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %)
  • Figure 86 Europe Decentralised Clinical Trials Market Share Forecast by Component, 2024 & 2034 (%)
  • Figure 87 Germany Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 88 France Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 89 UK Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 90 Italy Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 91 Spain Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 92 Russia Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 93 Poland Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 94 Belgium Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 95 Rest of Europe Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 96 Asia Pacific Decentralised Clinical Trials Market Attractiveness Index
  • Figure 97 Asia Pacific Decentralised Clinical Trials Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 98 Asia Pacific Decentralised Clinical Trials Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 99 Asia Pacific Decentralised Clinical Trials Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 100 Asia Pacific Decentralised Clinical Trials Market Forecast by Study Design, 2024-2034 (US$ Million, AGR %)
  • Figure 101 Asia Pacific Decentralised Clinical Trials Market Share Forecast by Study Design, 2024 & 2034 (%)
  • Figure 102 Asia Pacific Decentralised Clinical Trials Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 103 Asia Pacific Decentralised Clinical Trials Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 104 Asia Pacific Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 105 Asia Pacific Decentralised Clinical Trials Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 106 Asia Pacific Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %)
  • Figure 107 Asia Pacific Decentralised Clinical Trials Market Share Forecast by Component, 2024 & 2034 (%)
  • Figure 108 Japan Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 109 China Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 110 India Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 111 Australia Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 112 South Korea Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 113 Singapore Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 114 Taiwan Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 115 Rest of Asia Pacific Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 116 Latin America Decentralised Clinical Trials Market Attractiveness Index
  • Figure 117 Latin America Decentralised Clinical Trials Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 118 Latin America Decentralised Clinical Trials Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 119 Latin America Decentralised Clinical Trials Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 120 Latin America Decentralised Clinical Trials Market Forecast by Study Design, 2024-2034 (US$ Million, AGR %)
  • Figure 121 Latin America Decentralised Clinical Trials Market Share Forecast by Study Design, 2024 & 2034 (%)
  • Figure 122 Latin America Decentralised Clinical Trials Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 123 Latin America Decentralised Clinical Trials Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 124 Latin America Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 125 Latin America Decentralised Clinical Trials Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 126 Latin America Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %)
  • Figure 127 Latin America Decentralised Clinical Trials Market Share Forecast by Component, 2024 & 2034 (%)
  • Figure 128 Brazil Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 129 Mexico Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 130 Argentina Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 131 Colombia Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 132 Rest of Latin America Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 133 MEA Decentralised Clinical Trials Market Attractiveness Index
  • Figure 134 MEA Decentralised Clinical Trials Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 135 MEA Decentralised Clinical Trials Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 136 MEA Decentralised Clinical Trials Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 137 MEA Decentralised Clinical Trials Market Forecast by Study Design, 2024-2034 (US$ Million, AGR %)
  • Figure 138 MEA Decentralised Clinical Trials Market Share Forecast by Study Design, 2024 & 2034 (%)
  • Figure 139 MEA Decentralised Clinical Trials Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 140 MEA Decentralised Clinical Trials Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 141 MEA Decentralised Clinical Trials Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 142 MEA Decentralised Clinical Trials Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 143 MEA Decentralised Clinical Trials Market Forecast by Component, 2024-2034 (US$ Million, AGR %)
  • Figure 144 MEA Decentralised Clinical Trials Market Share Forecast by Component, 2024 & 2034 (%)
  • Figure 145 GCC Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 146 South Africa Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 147 Rest of MEA Decentralised Clinical Trials Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 148 Decentralised Clinical Trials Market Company Share, 2023
  • Figure 149 Dassault Systemes SE (Medidata Solutions, Inc.): Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 150 Dassault Systemes SE (Medidata Solutions, Inc.): R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 151 Dassault Systemes SE (Medidata Solutions, Inc.): Regional Market Shares (%), 2023
  • Figure 152 ICON Plc: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 153 ICON Plc: Regional Market Shares (%), 2023
  • Figure 154 IQVIA Inc.: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 155 IQVIA Inc.: Regional Market Shares (%), 2023
  • Figure 156 KORE Wireless Group, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR%)
  • Figure 157 KORE Wireless Group, Inc.: Regional Market Shares (%), 2023
  • Figure 158 Laboratory Corporation of America Holdings (Covance): Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 159 Laboratory Corporation of America Holdings (Covance): Regional Market Shares (%), 2023
  • Figure 160 Oracle Life Sciences: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 161 Oracle Life Sciences: Regional Market Shares (%), 2023
  • Figure 162 Syneos Health: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 163 Thermo Fisher Scientific Inc. (PPD): Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 164 Thermo Fisher Scientific Inc. (PPD): R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 165 Thermo Fisher Scientific Inc. (PPD): Regional Market Shares (%), 2023
  • Figure 166 Veeva Systems: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 167 Veeva Systems: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 168 Veeva Systems: Regional Market Shares (%), 2023
目次
Product Code: PHA1338

The global Decentralised Clinical Trials market is estimated to grow at a CAGR of 7.6% by 2034

The Decentralised Clinical Trials Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Globalisation of Clinical Trials

The globalization of clinical trials is fundamentally transforming the clinical trials market. The underline growth is driven by the expanding clinical trials that indicate towards a significant shift in the healthcare landscape. There is a growing need to accelerate drug development timelines, reduce costs, and access of innovative drugs to the diverse patient populations. The pharmaceutical and biotech companies invest heavily into conducting clinical trials to gather comprehensive clinical data across different countries. Gathering clinical data from diverse populations has a profound impact on the development and efficacy of medical treatments. By including participants from various ethnic, genetic, and socio-economic backgrounds, clinical trials can produce more comprehensive and generalizable data. This diversity helps in understanding how different groups respond to treatments, which can uncover variations in drug efficacy and potential side effects that might not be apparent in a homogenous study group.

Globalization is essential in promoting regulatory harmonization across various regions, offering substantial advantages to the clinical trials market. By standardizing regulatory guidelines and procedures internationally, pharmaceutical companies can more easily manage the intricate approval processes in multiple countries at once. This alignment minimizes redundant efforts and simplifies the development and authorization of new therapies. As a result, the time-to-market for cutting-edge treatments is reduced, allowing patients globally to access new medical innovations more quickly. Furthermore, a cohesive regulatory framework fosters increased collaboration and data exchange among researchers worldwide, improving the overall quality and effectiveness of clinical trials.

Concerns Related to Safety and Privacy of Clinical Trials Data

Digital clinical trials (DCTs) heavily rely on digital health technologies and remote data collection methods, making the protection of sensitive patient information a top priority. Concerns regarding data privacy and security can emerge from multiple sources, including unauthorized access to personal health data, breaches of electronic systems, and non-adherence to data protection regulations. Remote monitoring devices, mobile applications, and telemedicine platforms may gather a plethora of sensitive health information, spanning medical history, treatment details, and biometric data. Unauthorized access or misuse of this data could result in privacy breaches, identity theft, and reputational harm for both patients and research organizations.

Data transmission may occur across various platforms, devices, and geographical locations, heightening the risk of data exposure or interception during transit. Moreover, involving third-party vendors like technology providers and cloud service providers further complicates the data security landscape, as these entities may have access to sensitive patient information. Clinical trials often span multiple countries with differing legal jurisdictions, posing challenges in comprehending and adhering to data privacy requirements. Variations in local interpretations of privacy laws in relation to clinical trials contribute to this complexity.

What Questions Should You Ask before Buying a Market Research Report?

How is the decentralised clinical trials Market evolving?

What is driving and restraining the decentralised clinical trials market?

How will each decentralised clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each decentralised clinical trials submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading decentralised clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the decentralised clinical trials projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of decentralised clinical trials projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the decentralised clinical trials market?

Where is the decentralised clinical trials market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Decentralised Clinical Trials Market today, and over the next 10 years:

Our 321-page report provides 141 tables and 168 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Decentralised Clinical Trials Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Decentralised Clinical Trials prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Study Design

Interventional

Observational

Expanded access

Indication

Oncology

Cardiovascular

Immunology

Respiratory

Others

Component

Mobile Healthcare

Telemedicine

Wearable Devices

Web-based Technology

Others

End-users

Pharmaceutical and Biopharmaceutical Companies

CROs

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 27 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Poland

Belgium

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Colombia

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Decentralised Clinical Trials Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Castor

Clario

Clinical Ink

Cloudbyz

Dassault SystemesSE (Medidata Solutions, Inc.)

Ergomed Group

Florence Healthcare, Inc.

ICON Plc

IQVIA Inc.

KORE Wireless Group, Inc.

Laboratory Corporation of America Holdings (Covance)

Medable Inc.

Medrio

Oracle Life Sciences

Parexel International (MA) Corporation

ProPharma Group MIS Limited

Science 37

Signant Health (CRF Bracket)

Syneos Health

Thermo Fisher Scientific Inc. (PPD)

Veeva Systems

Overall world revenue for Decentralised Clinical Trials Market, 2024 to 2034 in terms of value the market will surpass US$9,200.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Decentralised Clinical Trials Market, 2024 to 2034 report help you?

In summary, our 320+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Decentralised Clinical Trials Market, 2024 to 2034, with forecasts for study design, indication, end-users and component, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 27 key national markets - See forecasts for the Decentralised Clinical Trials Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 20 of the major companies involved in the Decentralised Clinical Trials Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Decentralised Clinical Trials Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Decentralised Clinical Trials Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Advancements in Digital Health Technologies
      • 3.2.1.2 Globalisation of Clinical Trials
      • 3.2.1.3 Increasing Demand for Real-World Evidence
      • 3.2.1.4 Regulatory Support and Guidance
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Data Privacy and Security Concerns
      • 3.2.2.2 Technological Limitations and Standardization
      • 3.2.2.3 Infrastructure and Resource Constraints
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Acceleration of Drug Development and Innovation
      • 3.2.3.2 Expansion of Clinical Trial Activities into Emerging Markets
      • 3.2.3.3 Increasing Partnerships and Collaborations Between Pharmaceutical Companies
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat of Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Decentralised Clinical Trials Market Analysis by Study Design

  • 4.1 Key Findings
  • 4.2 Study Design Segment: Market Attractiveness Index
  • 4.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 4.4 Interventional
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Observational
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Expanded Access
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Decentralised Clinical Trials Market Analysis by Indication

  • 5.1 Key Findings
  • 5.2 Study Design Segment: Market Attractiveness Index
  • 5.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 5.4 Oncology
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Cardiovascular
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Immunology
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Respiratory
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Others
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)

6 Decentralised Clinical Trials Market Analysis by End-users

  • 6.1 Key Findings
  • 6.2 End-user Segment: Market Attractiveness Index
  • 6.3 Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 6.4 Pharmaceutical & Biopharmaceutical Companies
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Clinical Research Organisations (CROs)
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Others
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)

7 Decentralised Clinical Trials Market Analysis by Component

  • 7.1 Key Findings
  • 7.2 Component Segment: Market Attractiveness Index
  • 7.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 7.4 Mobile Healthcare
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Telemedicine
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Wearable Devices
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)
  • 7.7 Web-based Technology
    • 7.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.7.2 Market Share by Region, 2024 & 2034 (%)
  • 7.8 Others
    • 7.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.8.2 Market Share by Region, 2024 & 2034 (%)

8 Decentralised Clinical Trials Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Decentralised Clinical Trials Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Decentralised Clinical Trials Market Attractiveness Index
  • 9.3 North America Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 9.4 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Country
  • 9.5 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 9.6 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 9.7 North America Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 9.8 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 9.9 U.S. Decentralised Clinical Trials Market Analysis
  • 9.10 Canada Decentralised Clinical Trials Market Analysis

10 Europe Decentralised Clinical Trials Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Decentralised Clinical Trials Market Attractiveness Index
  • 10.3 Europe Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Country
  • 10.5 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 10.6 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 10.7 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 10.8 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 10.9 Germany Decentralised Clinical Trials Market Analysis
  • 10.10 France Decentralised Clinical Trials Market Analysis
  • 10.11 UK Decentralised Clinical Trials Market Analysis
  • 10.12 Italy Decentralised Clinical Trials Market Analysis
  • 10.13 Spain Decentralised Clinical Trials Market Analysis
  • 10.14 Russia Decentralised Clinical Trials Market Analysis
  • 10.15 Poland Decentralised Clinical Trials Market Analysis
  • 10.16 Belgium Decentralised Clinical Trials Market Analysis
  • 10.17 Rest of Europe Decentralised Clinical Trials Market Analysis

11 Asia Pacific Decentralised Clinical Trials Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Decentralised Clinical Trials Market Attractiveness Index
  • 11.3 Asia Pacific Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 11.6 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 11.7 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 11.8 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 11.9 Japan Decentralised Clinical Trials Market Analysis
  • 11.10 China Decentralised Clinical Trials Market Analysis
  • 11.11 India Decentralised Clinical Trials Market Analysis
  • 11.12 Australia Decentralised Clinical Trials Market Analysis
  • 11.13 South Korea Decentralised Clinical Trials Market Analysis
  • 11.14 Singapore Decentralised Clinical Trials Market Analysis
  • 11.15 Taiwan Decentralised Clinical Trials Market Analysis
  • 11.16 Rest of Asia Pacific Decentralised Clinical Trials Market Analysis

12 Latin America Decentralised Clinical Trials Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Decentralised Clinical Trials Market Attractiveness Index
  • 12.3 Latin America Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Country
  • 12.5 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 12.6 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 12.7 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 12.8 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 12.9 Brazil Decentralised Clinical Trials Market Analysis
  • 12.10 Mexico Decentralised Clinical Trials Market Analysis
  • 12.11 Argentina Decentralised Clinical Trials Market Analysis
  • 12.12 Colombia Decentralised Clinical Trials Market Analysis
  • 12.13 Rest of Latin America Decentralised Clinical Trials Market Analysis

13 MEA Decentralised Clinical Trials Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Decentralised Clinical Trials Market Attractiveness Index
  • 13.3 MEA Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Country
  • 13.5 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
  • 13.6 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
  • 13.7 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
  • 13.8 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Component
  • 13.9 GCC Decentralised Clinical Trials Market Analysis
  • 13.10 South Africa Decentralised Clinical Trials Market Analysis
  • 13.11 Rest of MEA Decentralised Clinical Trials Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2023
  • 14.2 Strategic Outlook
  • 14.3 Castor
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Product Benchmarking
    • 14.3.4 Strategic Outlook
  • 14.4 Clario
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Product Benchmarking
    • 14.4.4 Strategic Outlook
  • 14.5 Clinical Ink
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Product Benchmarking
    • 14.5.4 Strategic Outlook
  • 14.6 CLOUDZBYZ, Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Product Benchmarking
    • 14.6.4 Strategic Outlook
  • 14.7 Dassault Systemes SE (Medidata Solutions, Inc.)
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2017-2023
      • 14.7.3.2 R&D, 2017-2023
      • 14.7.3.3 Regional Market Shares, 2023
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Ergomed Group
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Product Benchmarking
    • 14.8.4 Strategic Outlook
  • 14.9 Florence Healthcare, Inc.
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Product Benchmarking
    • 14.9.4 Strategic Outlook
  • 14.10 ICON Plc
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2017-2023
      • 14.10.3.2 Regional Market Shares, 2023
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 IQVIA Inc.
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2017-2023
      • 14.11.3.2 Regional Market Shares, 2022
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 KORE Wireless Group, Inc.
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2019-2023
      • 14.12.3.2 Regional Market Shares, 2023
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 Laboratory Corporation of America Holdings (Covance)
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2017-2023
      • 14.13.3.2 Regional Market Shares, 2022
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Medable Inc.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
    • 14.14.4 Strategic Outlook
  • 14.15 Medrio
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Product Benchmarking
  • 14.16 Oracle Life Sciences
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2023
      • 14.16.3.2 Regional Market Shares, 2022
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook
  • 14.17 Parexel International (MA) Corporation
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Product Benchmarking
    • 14.17.4 Strategic Outlook
  • 14.18 ProPharma Group MIS Limited
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Product Benchmarking
    • 14.18.4 Strategic Outlook
  • 14.19 Science 37
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Product Benchmarking
    • 14.19.4 Strategic Outlook
  • 14.20 Signant Health (CRF Bracket)
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Product Benchmarking
    • 14.20.4 Strategic Outlook
  • 14.21 Syneos Health
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2017-2022
    • 14.21.4 Product Benchmarking
    • 14.21.5 Strategic Outlook
  • 14.22 Thermo Fisher Scientific Inc. (PPD)
    • 14.22.1 Company Snapshot
    • 14.22.2 Company Overview
    • 14.22.3 Financial Analysis
      • 14.22.3.1 Net Revenue, 2017-2023
      • 14.22.3.2 R&D, 2017-2023
      • 14.22.3.3 Regional Market Shares, 2023
    • 14.22.4 Product Benchmarking
    • 14.22.5 Strategic Outlook
  • 14.23 Veeva Systems
    • 14.23.1 Company Snapshot
    • 14.23.2 Company Overview
    • 14.23.3 Financial Analysis
      • 14.23.3.1 Net Revenue, 2017-2023
      • 14.23.3.2 R&D, 2017-2023
      • 14.23.3.3 Regional Market Shares, 2023
    • 14.23.4 Product Benchmarking
    • 14.23.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players